Research programme: Bispecific antibody therapeutics - Hanmi Pharmaceutical/ Innovent Biologics

Drug Profile

Research programme: Bispecific antibody therapeutics - Hanmi Pharmaceutical/ Innovent Biologics

Alternative Names: PD-1/TAA1 bispecific antibody; PD-1/TAA2 bispecific antibody; PD-1/TAA3 bispecific antibody

Latest Information Update: 13 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hanmi Pharmaceutical
  • Developer Hanmi Pharmaceutical; Innovent Biologics
  • Class Antineoplastics; Bispecific antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 30 Mar 2017 Hanmi Pharmaceutical and Innovent Biologics agree to co-promote and co-develop bispecific antibodies in the World for Cancer
  • 30 Mar 2017 Preclinical trials in Solid tumours in China and South Korea (Parenteral)
  • 30 Mar 2017 Hanmi Pharmaceutical and Innovent Biologics plan a clinical trial for Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top